Insmed incorporatedINSM.US Overview
INSM Overall Performance
INSM AI Analysis & Strategy
INSM Recent Performance
3.16%
Insmed incorporated
0.81%
Avg of Sector
-1.14%
S&P500
INSM PowerScanner
INSM Key Information
INSM Valuation Metrics
INSM Earnings Table
INSM Profile
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.